Discover
MENS
Jyong Biotech Ltd.
1.82
2 x 1.51
2 x 2.56
bid
ask
-
0.16
7.83%
02:18 PM
timesize
| Ytd | -53.80% | |
| 1y | -96.88% |
1.81
day range
2.02
1.43
52 week range
63.00
| Open | 1.97 | Prev Close | 1.98 | Low | 1.81 | High | 2.02 | Mkt Cap | 138.75M |
| Vol | 29.90K | Avg Vol | 45.65K | EPS | -0.06 | P/E | N/A | Forward P/E | N/A |
| Beta | 2.38 | Short Ratio | 0.56 | Inst. Own | 0.14% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 2.12 | 200-d Avg | 2.26 | 1yr Est | 0.00 |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|
Profile
Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-09-29 | Geode Capital Management, LLC | 53.84K | 157.22K | 0.07% |
| 2025-09-29 | HRT Financial LP | 20.82K | 60.79K | 0.03% |
| 2025-09-29 | Millennium Management Llc | 13.01K | 38.00K | 0.02% |
| 2025-09-29 | Citadel Advisors Llc | 12.64K | 36.91K | 0.02% |
| 2025-09-29 | BNP Paribas Financial Markets | 1.70K | 4.96K | 0.00% |
| 2025-09-29 | UBS Group AG | 537.00 | 1.57K | 0.00% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-09-29 | Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 35.80K | 104.54K | 0.05% |
| 2025-09-29 | Fidelity Commonwealth Trust-Fidelity Nasdaq Composite Index ETF | 18.04K | 52.68K | 0.02% |